Complementary treatment of allergic rhinoconjunctivitis: the role of the nutraceutical Lertal(R)

Research output: Contribution to journalArticlepeer-review

Abstract

Nutraceuticals represent interesting therapeutic options in clinical practice. In this regard, a new compound has been designed: Lertal®. It contains quercetin, perilla extract, and vitamin D3. These agents exert anti-allergic and anti-inflammatory activities. This article reports and discusses the results of four clinical studies conducted in adult and paediatric patients suffering from AR. Outcomes provided evidence that Lertal® may significantly prevent clinical worsening when prescribed as add-on to continuous antihistaminic treatment and also prevent clinical exacerbations, such as the need of rescue medication, when used alone as preventive strategy in AR patients.

Original languageEnglish
Pages (from-to)97-106
Number of pages10
JournalActa bio-medica : Atenei Parmensis
Volume91
Issue number1
DOIs
Publication statusPublished - Mar 19 2020

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Complementary treatment of allergic rhinoconjunctivitis: the role of the nutraceutical Lertal(R)'. Together they form a unique fingerprint.

Cite this